Three Luye Pharma Products Included in National Reimbursement Drug List

MT Newswires Live11-28

Several innovative products by Luye Pharma Group (HKG:2186) have been included in the National Reimbursement Drug List for basic medical insurance, work-related injury insurance, and maternity insurance, a Thursday bourse filing said.

Antidepressant Ruoxinlin has been included in the list for the time, cancer drug Baituowei has made it for a new indication for breast cancer, and tumor drug Lipusu is included in the regular catalogue of the list.

The list will officially take effect on Jan. 1, 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment